Glencore’s Aluminum Gambit

The acquisition, reported in a predictably dry SEC filing, elevates Century Aluminum to a commanding 48.39% of Glencore’s reported assets. A curious concentration, wouldn’t you agree? One recalls the cautionary tales of portfolios built on a single, glittering foundation. Still, one must admire the boldness, or perhaps the sheer lack of alternatives.

Lost Bitcoin, Found Regrets: Dogecoin Founder Feels the Pain

In a recent post on the intergalactic communication platform X (formerly known as Twitter, or as I like to call it, the place where dreams go to argue with strangers), Markus shared an image that would make even the most stoic of time travelers weep into their space-time lattes. The headline? A poor soul lost a staggering amount of Bitcoin 12 years ago. We’re talking enough Bitcoin to make you a multimillionaire, or as I like to say, enough to buy a small moon.

Quantum Shadows: A Reckoning in 2026

The numbers, when examined without the haze of promotional fervor, possess a certain melancholy. D-Wave, a pioneer burdened by the weight of its early promises, commands a market capitalization of ten billion dollars despite trailing twelve-month sales barely exceeding twenty-four million. Rigetti, a company that once dreamt of building a quantum fortress, has managed a modest twelve and a half million in revenue, yet its value hovers around eight and a half billion. Quantum Computing, a fledgling enterprise, boasts a market cap of nearly three billion dollars on a mere half a million in revenue. These are not valuations; they are prayers whispered into the void.

Planet Labs: A Fleeting Orbit

Last quarter’s earnings were, shall we say, adequate. Revenue grew by a respectable thirty-three percent to eighty-one million dollars. A figure that, in the grand scheme of things, is less a roaring fire and more a flickering candle. However, their backlog – a delightful accumulation of promised future revenue – swelled by an astonishing two hundred and sixteen percent to seven hundred and thirty-four million. A paper mountain of potential, if you will. More and more entities – both those dedicated to the art of war and those simply obsessed with quarterly reports – are turning to Planet Labs for their aerial perspectives. They even entertain notions of constructing data centers in orbit. The sheer audacity! One pictures a celestial bureaucracy, endlessly filing paperwork amongst the stars.

AMD: When Intel Stumbles, Chips Are Up

AMD shares, as of this morning, have gained a respectable 3.8%. The question isn’t that they’ve gone up, it’s why. It’s rarely about simple good news, is it? More often, it’s about someone else’s bad news looking particularly good by comparison. Like finding a slightly less mouldy loaf in a bakery fire.

Trinity Capital: A Dividend and a Departure

According to a filing on January 20th, GraniteShares just… let it go. A $3.29 million decrease in their position. Zero stake remaining. It’s a bit dramatic, really. One minute you’re in, the next… poof. Makes you wonder if there was a fight. A financial fight, obviously.

NNN REIT: A Study in Durable Yield

My own inclination, in navigating these uncertain waters, has led me to a particular class of investment: the high-quality dividend stock. And recently, after a period of observation, I added NNN REIT (NNN 0.17%) to my holdings. It is not a glamorous choice, perhaps, lacking the disruptive sheen of the new technologies, but it possesses a certain…sturdiness. A quality that, in these times, feels profoundly reassuring.

Silicon & Snow: Two Stocks for a Coming Spring

Nvidia, and Broadcom. These are not simply companies; they are currents in the rising tide of artificial intelligence. Should the projections hold—and the scent of possibility is strong—they could reshape portfolios, alter the very landscape of investment. One is the broad plain, the other a hidden spring. Both essential.

Pfizer: A Seed in Barren Ground

Pharmacist and Patient

Pfizer. The name itself holds a weight, a history etched into the very fabric of modern medicine. And now, it finds itself in a curious position. A period of transition, a shedding of old growth. The loss of patent exclusivity is not a death, but a dormancy. A necessary retreat before the next flowering. It is as if the company, having reached a certain height, is allowing some branches to fall, preparing for a new, perhaps more resilient, form.